Halofantrine hydrochloride - Generic Drug Details

What are the generic drug sources for halofantrine hydrochloride and what is the scope of freedom to operate?

Halofantrine hydrochloride is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for halofantrine hydrochloride

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	7
DailyMed Link:	halofantrine hydrochloride at DailyMed

Recent Clinical Trials for halofantrine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Papua New Guinea Institute of Medical Research	Phase 3
Lihir Medical Centre	Phase 3
Barcelona Institute for Global Health	Phase 3

See all halofantrine hydrochloride clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for halofantrine hydrochloride

P01BX	Other antimalarials
P01B	ANTIMALARIALS
P01	ANTIPROTOZOALS
P	Antiparasitic products, insecticides and repellents

US Patents and Regulatory Information for halofantrine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	HALFAN	halofantrine hydrochloride	TABLET;ORAL	020250-001	Jul 24, 1992		DISCN	No	No

Halofantrine Hydrochloride Market Dynamics, Patent Status, and Financial Trajectory

Last updated: September 4, 2026

Halofantrine hydrochloride is an older antimalarial with no meaningful current U.S. commercial market. Its commercial trajectory peaked after U.S. approval of Halfan in 1992, then deteriorated as cardiac safety concerns, limited treatment positioning, weak access economics, and competition from artemisinin-based therapies reduced demand. The drug has no active U.S. regulatory exclusivity, no biosimilar pathway, and limited strategic value for most pharmaceutical companies.

What is the current market status of halofantrine hydrochloride?

Halofantrine hydrochloride is a phenanthrene-methanol antimalarial developed for treatment of acute, uncomplicated malaria. Halfan, the branded product, was approved in the United States in 1992 for adults and children, but it is no longer an active U.S. commercial product.[1]

Market factor	Current assessment
Active U.S. branded product	No
U.S. FDA approval history	Halfan approved in 1992
Current U.S. availability	Not commercially active
Primary indication	Acute, uncomplicated malaria
Disease focus	Primarily Plasmodium falciparum and other susceptible malaria infections
Treatment positioning	Superseded by artemisinin-based combination therapies
U.S. patent exclusivity	Expired
U.S. regulatory exclusivity	Expired
Biosimilar exposure	Not applicable
Generic opportunity	Technically possible, commercially limited
Major barrier	QT prolongation and potentially fatal ventricular arrhythmias

Halofantrine is not a current first-line antimalarial in major international treatment guidelines. The World Health Organization has favored artemisinin-based combination therapies because of efficacy, resistance management, and more favorable clinical positioning.[2]

When did halofantrine lose exclusivity?

Halofantrine’s U.S. patent protection expired years ago. The original product was developed and commercialized in the late twentieth century, meaning any ordinary U.S. composition or product patents associated with the initial launch would have expired no later than the statutory life of those patents.

A precise patent-expiration date for the principal halofantrine patent family is not necessary to assess present commercial exposure: no active U.S. market exclusivity protects the drug today. The product’s economic decline reflects commercial and clinical displacement rather than a pending loss of exclusivity.

Halofantrine exclusivity timeline

Period	Event	Commercial effect
1980s	Development and international commercialization of halofantrine	Established the original product franchise
1992	U.S. FDA approval of Halfan	Created U.S. prescription-market access
1990s	Safety warnings and restrictions related to QT prolongation	Reduced physician adoption and treatment flexibility
Late 1990s to 2000s	Expansion of artemisinin-based therapies	Reduced competitive relevance
2000s	Expiration of original patent protection	Removed legal barriers to generic development
2010s onward	Decline of branded and international commercial activity	Reduced market size and investment rationale
Current	No meaningful U.S. exclusivity or active branded franchise	Primarily a legacy product

What patents protect halofantrine hydrochloride?

No active U.S. patent estate with meaningful commercial blocking power is associated with halofantrine hydrochloride today.

Historical protection would have centered on:

• The halofantrine chemical entity.
• Pharmaceutical salts, including halofantrine hydrochloride.
• Oral dosage forms and solid formulations.
• Methods of treating malaria.
• Manufacturing processes and intermediates.

The original compound patents and related product protection are understood to be expired. Any remaining patent activity would need to be assessed at the jurisdictional and claim level, particularly for countries with different patent-term rules or later-filed process claims.

Are formulation patents still relevant?

Formulation patents are unlikely to create a material U.S. barrier. Halofantrine hydrochloride was principally supplied as oral tablets and oral suspension. The product’s commercial problem is not the absence of a protected formulation. It is the limited clinical and regulatory demand for a drug with recognized cardiac risk.

A new formulation could theoretically target:

• Improved absorption.
• Lower peak plasma exposure.
• Reduced food-effect variability.
• Pediatric dosing.
• Fixed-dose combinations.
• Modified release.
• Alternative delivery systems.

Those opportunities would require new clinical evidence and regulatory positioning. A formulation patent alone would not restore the original market without a credible safety and efficacy advantage.

What is the FDA regulatory status of halofantrine hydrochloride?

The FDA approved Halfan for treatment of acute, uncomplicated malaria. The product labeling warned against use in patients with known QT prolongation, a history of ventricular arrhythmias, clinically significant bradycardia, or other conditions that increase the risk of torsades de pointes.[1]

The label also identified important interaction risks. Halofantrine exposure can increase when combined with drugs that inhibit metabolism or prolong the QT interval. The cardiac warning limited use in patients who might otherwise have received an oral antimalarial empirically.

The key regulatory distinction is:

• The FDA approved the product historically.
• The product is not an active U.S. commercial franchise.
• The historical approval does not create current market exclusivity.
• Discontinuation of commercial distribution does not convert the drug into a current exclusivity opportunity.

What is the Orange Book status of halofantrine?

The Orange Book is relevant to halofantrine primarily as a historical record of FDA-approved drug products and patent listings. There is no current commercial Halfan franchise with an active patent listing that would materially delay an abbreviated new drug application.

A prospective generic applicant would still need to confirm the current FDA product record, reference-product designation, and any regulatory requirements associated with an inactive or discontinued reference drug. The key business point is that Orange Book patent protection is not the principal obstacle. Clinical risk, market demand, and reference-product strategy are more important.

Does halofantrine face Paragraph IV challenges?

No commercially significant current Paragraph IV campaign is publicly associated with halofantrine hydrochloride.

Paragraph IV litigation is generally relevant when:

1. A branded reference product remains commercially valuable.
2. Active patents are listed in the Orange Book.
3. A generic applicant expects meaningful sales after approval.
4. The brand owner has a financial incentive to litigate.

Those conditions are not present at scale for halofantrine. Historical patent expiry removed the main litigation incentive, while the small and fragmented market reduced the expected return from an ANDA challenge.

A generic applicant could still pursue an abbreviated pathway if the FDA’s reference-product and bioequivalence requirements were satisfied. That would be a regulatory execution question rather than a patent-litigation contest.

What patent litigation affects halofantrine hydrochloride?

No major current U.S. patent litigation materially affects halofantrine hydrochloride.

The principal disputes surrounding the drug have historically been more closely connected to safety, labeling, availability, and clinical use than to an active patent enforcement program. No current litigation campaign comparable to those seen for high-revenue oncology, immunology, or specialty drugs defines the halofantrine market.

Is there biosimilar risk for halofantrine?

No. Biosimilar regulation applies to biologic products, while halofantrine hydrochloride is a small-molecule drug. Competitive entry would occur through a generic-drug pathway, not through a biosimilar application.

Potential competitors would need to address:

• Pharmaceutical equivalence.
• Bioequivalence.
• Active-ingredient quality.
• Dissolution and absorption.
• Tablet or suspension manufacturing.
• Labeling and safety restrictions.
• The commercial viability of a small antimalarial market.

How strong is the halofantrine patent estate?

The current patent estate is weak from a commercial blocking perspective.

Patent-estate category	Assessment
Core composition patent	Expired
Salt protection	Expired or commercially ineffective
Oral tablet protection	No meaningful current U.S. barrier identified
Suspension formulation	Limited strategic value
Method-of-use protection	Expired or not commercially blocking
Manufacturing patents	Potentially relevant in narrow jurisdictions, but unlikely to support a large franchise
Regulatory exclusivity	Expired
Litigation leverage	Low
International residual value	Possible in isolated markets, but not sufficient to support broad investment

A stronger estate would require a newly developed formulation or combination supported by new clinical data. The investment would resemble redevelopment of a legacy drug rather than monetization of an existing patent franchise.

What competitive drugs displaced halofantrine?

Artemisinin-based combination therapies displaced halofantrine in most major treatment programs. Common alternatives include artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, and other nationally recommended combinations.[2]

Drug or class	Market position relative to halofantrine
Artemether-lumefantrine	Widely used first-line combination in many malaria programs
Artesunate-based regimens	Core treatment for severe malaria and important hospital use
Dihydroartemisinin-piperaquine	Used in several endemic markets
Atovaquone-proguanil	Important travel-medicine and prophylaxis product
Mefloquine	Used selectively because of neuropsychiatric and other safety concerns
Quinine	Legacy therapy with tolerability and dosing disadvantages
Halofantrine	Limited or obsolete role because of cardiac safety and treatment alternatives

Halofantrine’s position weakened for two reasons. First, alternative drugs achieved stronger public-health adoption. Second, halofantrine’s cardiac liability limited use in settings where rapid treatment decisions were required and electrocardiographic screening was unavailable.

What are the generic launch risks for halofantrine?

A generic launch would face low patent risk but high commercial risk.

Regulatory and technical barriers

The drug has several technical issues that can complicate development:

• Variable oral absorption.
• Food-dependent changes in bioavailability.
• Dose-related cardiac risk.
• Potential QT prolongation.
• Drug-drug interactions.
• Pediatric dosing complexity.
• Need for reliable active-ingredient supply.
• Limited clinical demand for a product that is not guideline-preferred.

A generic company could obtain legal market access and still fail to achieve acceptable returns. The most likely launch model would be a niche supply product for selected countries, hospitals, military buyers, or malaria-treatment programs rather than a broad U.S. retail launch.

Manufacturing and supply-chain barriers

The active pharmaceutical ingredient is a specialized antimalarial with limited global demand. That creates several risks:

• Few qualified suppliers.
• Low manufacturing scale.
• Long inventory cycles.
• Difficulties maintaining commercial registration.
• Limited willingness of contract manufacturers to support small volumes.
• Procurement substitution by preferred artemisinin-based products.

Manufacturing know-how is unlikely to be a durable patent barrier, but supply economics may still prevent new entrants from achieving scale.

What is the financial trajectory of halofantrine?

Halofantrine followed a typical legacy-drug decline:

1. Commercial launch after regulatory approval.
2. Early demand from malaria treatment markets.
3. Safety restrictions and reduced clinical confidence.
4. Displacement by newer guideline-preferred therapies.
5. Patent expiry and generic commoditization.
6. Commercial withdrawal or severe market contraction.

No reliable, current public disclosure provides standalone revenue for halofantrine hydrochloride. Historical revenue was generally embedded in broader company reporting and is not consistently separable from other anti-infective products. The absence of a current branded franchise means there is no meaningful present revenue stream comparable to an active specialty pharmaceutical.

Revenue exposure by market

Revenue source	Current outlook
U.S. branded sales	Minimal to none
U.S. generic sales	Commercially unattractive without a contracted buyer
European branded sales	Limited and fragmented
Endemic-country public procurement	Potentially available but highly price-sensitive
Travel medicine	Limited relative to atovaquone-proguanil and other alternatives
Hospital use	Restricted by safety and guideline position
Licensing income	No material current stream identified
Combination-product opportunity	Theoretical, but requires new evidence and investment

The asset has low current revenue exposure for any major multinational pharmaceutical company. Its value is more likely to arise from a narrowly targeted regional supply arrangement than from a global brand relaunch.

Are there licensing deals involving halofantrine?

No current high-value licensing transaction is publicly associated with halofantrine hydrochloride.

The historical commercial rights were connected to the original developers and marketers of Halfan, including the legacy SmithKline Beecham organization. Those corporate assets were later absorbed into larger pharmaceutical structures, but the product no longer represents a material strategic licensing platform.

A new licensing transaction would likely require one of three conditions:

• A low-cost access program in malaria-endemic countries.
• A new formulation designed to mitigate cardiac or absorption concerns.
• A combination product with clinical evidence that improves treatment utility.

Without such differentiation, licensing value is limited by the drug’s safety profile and weak market position.

How does halofantrine compare with modern antimalarial products?

Halofantrine has a weaker commercial and regulatory profile than current first-line antimalarial therapies.

Attribute	Halofantrine hydrochloride	Artemisinin-based combinations
Current guideline position	Limited or generally disfavored	Preferred in many malaria settings
Cardiac risk	Significant QT concern	Product-specific, generally more manageable in routine use
Market access	Fragmented	Supported by national programs and global procurement
Patent position	Expired	Varies by product and jurisdiction
Generic competition	Possible	Extensive for several products
Revenue potential	Low	Higher where procurement volumes are substantial
Clinical differentiation	Weak	Stronger public-health positioning
Development appeal	Low	Higher for improved combinations and formulations

What is the outlook for halofantrine hydrochloride?

The base-case outlook is continued commercial contraction, not recovery.

A limited residual market may persist where:

• Existing national registrations remain active.
• Clinicians have familiarity with the product.
• Procurement systems prioritize low-cost legacy medicines.
• Alternative antimalarials are unavailable.
• A supplier maintains manufacturing and regulatory support.

A broad U.S. relaunch is unlikely without substantial new evidence addressing cardiac safety. A new formulation could generate patentable subject matter, but the development cost and regulatory burden would be difficult to justify against the small addressable market.

Key Takeaways

• Halofantrine hydrochloride is a legacy antimalarial with no meaningful current U.S. commercial franchise.
• Halfan received FDA approval in 1992, but its commercial position deteriorated because of QT prolongation risk and competition from artemisinin-based therapies.
• Core patent protection and regulatory exclusivity have expired.
• No major current Paragraph IV campaign or patent litigation materially affects the drug.
• Biosimilar risk does not apply because halofantrine is a small-molecule drug.
• Generic entry is legally feasible but commercially unattractive without institutional procurement.
• Formulation or combination patents could support redevelopment, but only with new clinical evidence.
• Current financial value is likely limited to fragmented regional supply, not a global branded opportunity.

FAQs

Is halofantrine hydrochloride still sold in the United States?

No meaningful active U.S. commercial market exists for Halfan. The FDA approval history remains relevant, but the product is not a current mainstream U.S. antimalarial.

Can a generic company still develop halofantrine tablets?

Yes, subject to FDA reference-product, bioequivalence, quality, and labeling requirements. The larger obstacle is limited demand and the drug’s cardiac safety profile.

Is halofantrine hydrochloride on the WHO essential medicines list?

Halofantrine is not a preferred component of current WHO malaria treatment policy. WHO guidance emphasizes artemisinin-based combination therapies for uncomplicated malaria.[2]

Does halofantrine have a market in Africa?

Any remaining use is likely fragmented and country-specific. National treatment guidelines, procurement decisions, registration status, and availability of artemisinin-based products determine actual demand.

Could a new halofantrine formulation obtain new patents?

Potentially. A genuinely novel formulation, combination, or delivery system could support new patent claims. Patentability would not by itself establish commercial value, because clinical redevelopment and regulatory acceptance would remain necessary.

References

1. U.S. Food and Drug Administration. (1992). Halfan (halofantrine hydrochloride) prescribing information. U.S. Department of Health and Human Services.

2. World Health Organization. (2023). Guidelines for malaria. World Health Organization.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. World Health Organization. (2023). World malaria report 2023. World Health Organization.